Free Trial

MiNK Therapeutics (INKT) Competitors

MiNK Therapeutics logo
$14.98 +0.82 (+5.79%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$14.70 -0.29 (-1.90%)
As of 10/24/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INKT vs. FTFT, RENB, CRBU, OGI, ALTS, LFCR, AVIR, SGMT, CRBP, and HRTX

Should you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Future FinTech Group (FTFT), Lunai Bioworks (RENB), Caribou Biosciences (CRBU), Organigram Global (OGI), ALT5 Sigma (ALTS), Lifecore Biomedical (LFCR), Atea Pharmaceuticals (AVIR), Sagimet Biosciences (SGMT), Corbus Pharmaceuticals (CRBP), and Heron Therapeutics (HRTX).

MiNK Therapeutics vs. Its Competitors

Future FinTech Group (NASDAQ:FTFT) and MiNK Therapeutics (NASDAQ:INKT) are related small-cap companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Future FinTech Group has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500.

MiNK Therapeutics has a consensus target price of $37.50, indicating a potential upside of 150.33%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe MiNK Therapeutics is more favorable than Future FinTech Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Future FinTech Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
MiNK Therapeutics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.50

0.2% of Future FinTech Group shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 0.9% of Future FinTech Group shares are owned by company insiders. Comparatively, 22.5% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, MiNK Therapeutics had 3 more articles in the media than Future FinTech Group. MarketBeat recorded 4 mentions for MiNK Therapeutics and 1 mentions for Future FinTech Group. Future FinTech Group's average media sentiment score of 1.89 beat MiNK Therapeutics' score of 1.16 indicating that Future FinTech Group is being referred to more favorably in the media.

Company Overall Sentiment
Future FinTech Group Very Positive
MiNK Therapeutics Positive

MiNK Therapeutics has lower revenue, but higher earnings than Future FinTech Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Future FinTech Group$2.16M19.78-$32.96MN/AN/A
MiNK TherapeuticsN/AN/A-$9.51M-$2.88-5.20

MiNK Therapeutics' return on equity of 0.00% beat Future FinTech Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Future FinTech GroupN/A -347.16% -200.95%
MiNK Therapeutics N/A N/A -227.24%

Summary

MiNK Therapeutics beats Future FinTech Group on 9 of the 13 factors compared between the two stocks.

Get MiNK Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INKT vs. The Competition

MetricMiNK TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$67.73M$3.46B$6.21B$10.81B
Dividend YieldN/A2.28%5.72%4.80%
P/E Ratio-5.2028.5131.6030.98
Price / SalesN/A497.40595.06133.64
Price / CashN/A46.9537.2561.86
Price / Book-3.0310.4012.056.61
Net Income-$9.51M-$52.83M$3.34B$277.10M
7 Day Performance7.00%2.10%1.94%2.57%
1 Month Performance7.31%10.17%6.88%3.20%
1 Year Performance111.37%16.57%56.06%33.22%

MiNK Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INKT
MiNK Therapeutics
2.8644 of 5 stars
$14.98
+5.8%
$37.50
+150.3%
+113.4%$67.73MN/A-5.2030Positive News
Analyst Forecast
FTFT
Future FinTech Group
1.5179 of 5 stars
$2.06
-2.8%
N/A-34.6%$41.51M$2.16M0.0070Positive News
RENB
Lunai Bioworks
0.1779 of 5 stars
$1.54
+21.7%
N/A-69.8%$250.24MN/A-2.0020Gap Down
CRBU
Caribou Biosciences
2.819 of 5 stars
$2.63
-1.5%
$6.67
+153.5%
+40.7%$244.91M$9.99M-1.48100News Coverage
Positive News
Analyst Forecast
OGI
Organigram Global
0.8494 of 5 stars
$1.82
-3.7%
N/A-5.4%$244.50M$117.47M36.41860Positive News
Analyst Forecast
ALTS
ALT5 Sigma
0.3286 of 5 stars
$1.95
-11.0%
N/A-22.5%$243.65M$12.53M0.00170Gap Up
High Trading Volume
LFCR
Lifecore Biomedical
1.4506 of 5 stars
$6.49
-0.6%
$8.00
+23.3%
+23.4%$243.18M$128.87M-4.95690Analyst Forecast
AVIR
Atea Pharmaceuticals
2.2696 of 5 stars
$3.06
-1.9%
$6.00
+96.1%
-4.2%$242.84MN/A-1.9070News Coverage
Analyst Forecast
SGMT
Sagimet Biosciences
3.2029 of 5 stars
$7.36
-2.5%
$25.67
+248.7%
+63.5%$239.35M$2M-4.028News Coverage
Analyst Forecast
Gap Up
CRBP
Corbus Pharmaceuticals
4.2349 of 5 stars
$19.32
+1.4%
$45.43
+135.1%
+3.5%$236.86MN/A-4.0640News Coverage
Analyst Forecast
Analyst Revision
High Trading Volume
HRTX
Heron Therapeutics
4.0676 of 5 stars
$1.29
-0.8%
$4.50
+248.8%
-35.1%$236.48M$144.29M-64.50300News Coverage
Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:INKT) was last updated on 10/26/2025 by MarketBeat.com Staff
From Our Partners